Close Navigation
About Arix
Strategy
Overview
Investment Case
News
Results
Documents
Events
Calendar
Analysts
Stock info
Contact
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
About
Strategy
Team
Portfolio
Insights
Media
Contact
Investors
Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)
11th December 2020
Useful Tools
Download, print or share this article
Print Article
Email Article
Save Article
Share Article
Twitter
LinkedIn
Facebook